Last reviewed · How we verify
Evacetrapib Tablet
At a glance
| Generic name | Evacetrapib Tablet |
|---|---|
| Also known as | LY2484595 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Evacetrapib in High-Risk Vascular Disease (PHASE3)
- A Study of LY2484595 on Pharmacokinetics in Healthy Participants (PHASE1)
- A Study to Measure the Amount of Evacetrapib That Enters the Blood Stream in Healthy Participants (PHASE1)
- A Study of Different Particle Sizes of Evacetrapib in Healthy Participants (PHASE1)
- A Study of Evacetrapib in Healthy Japanese Participants (PHASE1)
- A Study of Evacetrapib (LY2484595) in Healthy Participants (PHASE1)
- A Study of LY2484595 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Evacetrapib Tablet CI brief — competitive landscape report
- Evacetrapib Tablet updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI